nicox sa (COX:EN Paris)
nicox sa (COX) Snapshot
|
Open
€2.55
|
Previous Close
€2.58
|
|
|
Day High
€2.58
|
Day Low
€2.52
|
|
|
52 Week High
01/23/13 - €3.75
|
52 Week Low
07/25/12 - €2.12
|
|
|
Market Cap
186.1M
|
Average Volume 10 Days
383.4K
|
|
|
EPS TTM
€-0.26
|
Shares Outstanding
73.0M
|
|
|
EX-Date
05/30/99
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
nicox sa (COX) Related Businessweek News
No Related Businessweek News Foundnicox sa (COX) Details
NicOx S.A. develops a portfolio of therapies and diagnostic tools to enhance sight in the United States, Europe, and internationally. It provides AdenoPlus a diagnostic test that offers eyecare professionals to diagnose and manage patients with an acute red eye. The company’s pipeline product, Latanoprostene bunod, is in Phase III clinical trails for the treatment of glaucoma and ocular hypertension. In addition, it engages in the research and development of nitric oxide steroids for the treatment of back and front of the eye disease; and NO-donors for eye disorder applications. Further, the company develops Naproxcinod, an anti-inflammatory candidate that is in regulatory review with the US Food and Drug Administration for the treatment of signs and symptoms of osteoarthritis; nitric oxide for cardiovascular indications; and NCX 1047, a dermatology anti-inflammatory drug-candidate, which is in preclinical stage of development. NicOx S.A. has collaboration with Bausch + Lomb, Merck, and Grupo Ferrer Internacional S.A. The company was founded in 1996 and is headquartered in Sophia Antipolis, France.
nicox sa (COX) Key Developments
Nicox SA Presents at Jefferies 2013 Global Healthcare Conference, Jun-04-2013 12:30 PM. Venue: Grand Hyatt Hotel, 109 East 42nd Street at Grand Central, New York, New York, United States. Speakers: Michele Garufi, Co-Founder, Chairman and Chief Executive Officer.
Nicox SA announced consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company’s revenues totaled EUR 0.07 million, compared to EUR 7.5 million for the same period of 2012, which included receipt of a significant milestone payment from Bausch + Lomb. Net loss was EUR 4.3 million compared to a net profit of EUR 4.2 million for the three months to March 31, 2012. This situation is explained by the strong decrease in revenues recognized over the period compared to the first three months of 2012 which included a significant milestone payment from partner Bausch + Lomb. Operating loss was EUR 4.3 million, compared to an operating profit of EUR 4 million on March 31, 2012. Loss before income tax was EUR 4,289,000 compared to profit before income tax of EUR 4,181,000 a year ago.
Nicox SA, Annual General Meeting, Jun 06, 2013., at 14:00 Central European Standard Time. Location: Hotel Mercure - rue Albert Caquot. Agenda: To consider the election of Vicente Anido, Jr., PhD., to its Board.

| Recently Viewed | |||
| COX:FP | €2.55 EUR | -0.03 | |
| Company | Last | Change | |
| No competitor information is available for COX. | |||
| View Industry Companies | |||
Industry Analysis
COX
Industry Average
| Valuation | COX | Industry Range |
| Price/Earnings | -- | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | -- | Not Meaningful |
| Price/Cash Flow | -- | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
- Orlando, FL | Consult SoftPosted: May 22
Sponsored Financial Commentaries
Sponsored Links
To contact NICOX SA, please visit www.nicox.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








